Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company. The firm focuses on the development of Salarius’ clinical pipeline, which targets rare, orphan cancers and cancers with a high unmet need. The company was founded in 2014 and is headquartered in Houston, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.

Online Event Scheduled for Monday, June 21, 2021, at 2:00 p.m., ET

REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be an open-label, dose-finding, dose-expansion study to determine the maximum tolerated dose and the safety & tolerability of seclidemstat in combination with azacytidine for Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.

Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat

Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML) Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML)

Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers

Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET

Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event

Salarius Pharmaceuticals Inc (NASDAQ: SLRX) presented data at the American Society of Clinical Oncology Virtual Annual Meeting for seclidemstat, a reversible inhibitor of the lysine-specific histone demethylase 1 (LSD1), an enzyme that plays a key role in the development and progression of several cancers. Data demonstrated that seclidemstat has a manageable safety profile, favorable pharmacokinetics that supports twice-daily (BID) oral dosing.

Salarius' Seclidemstat Shows Single-Agent Drug Activity in Heavily Pre-Treated Sarcomas Patients

The stock price of Salarius Pharmaceuticals Inc (NASDAQ: SLRX) increased by over 4% pre-market. This is why it happened.

SLRX Stock Price: Over 4% Increase Explanation

Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial

Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat's Safety, Dosing, and Drug Activity at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials

Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting

Ideanomics Inc

Mind Medicine MindMed

Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks On Robinhood For You May 2021 Watch List

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q1 2021 Results - Earnings Call Transcript

Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 72.73% year over year to ($0.06), which missed the estimate of ($0.05).

Salarius Pharmaceuticals: Q1 Earnings Insights

Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat

Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights

Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET Conference Call and Live Audio Webcast Scheduled for Wednesday, May 12, 2021, 5:00 p.m. ET

Salarius Pharmaceuticals to Report First Quarter 2021 Financial Results

HOUSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today the titles of the abstracts accepted for poster presentations during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. Salarius submitted three abstracts detailing research regarding seclidemstat, all of which have been accepted for poster presentations, with one abstract also selected for a poster discussion session. ASCO will be held virtually from June 4-8, 2021.

Salarius Pharmaceuticals Announces Titles of Three Abstracts Accepted for Poster Presentations at American Society of Clinical Oncology 2021 Annual Meeting

HOUSTON, April 19, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that all three submitted abstracts detailing research involving seclidemstat were accepted for poster presentations, with one abstract also selected for a poster discussion session, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. ASCO will be held virtually from June 4-8, 2021.

Salarius Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentations at the 2021 American Society of Clinical Oncology Annual Meeting

SLRX is a low market cap early-stage cancer therapeutics company. It has a very low cash reserve.

Salarius: Early Stage Nano Cap Targeting Cancer

Salarius Pharmaceuticals, Inc. (SLRX) CEO David Arthur on Q4 2020 Results - Earnings Call Transcript

Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 77.27% over the past year to ($0.10), which beat the estimate of ($0.11).

Recap: Salarius Pharmaceuticals Q4 Earnings

Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Today, Thursday, March 18, 2021, 4:30 p.m. ET

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results

Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, March 18, 2021, 4:30 p.m. ET

Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results

HOUSTON, March 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced the closing of its previously announced underwritten public offering of 16,806,722 shares of its common stock, including 2,192,181 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, at the public offering price of $1.3685 per share. As a result of the underwriters' over-allotment option exercise, the aggregate gross proceeds to Salarius from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $23 million.

Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option

HOUSTON, March 03, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has commenced an underwritten public offering of shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Salarius Announces Proposed Public Offering of Common Stock

PRA Health Sciences

Poseida Therapeutics

Sunesis Pharmaceuticals

A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of Merger Deal: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), a biopharma focused on developing targeted therapies for hematologic and solid cancers, filed its annual report on Form 10-K with the SEC.

Why Sunesis, Poseida, Salarius And PRA Health Are Rallying

The stock price of Salarius Pharmaceuticals Inc (NASDAQ: SLRX) is trading at over 20% pre-market. This is why it happened.

SLRX Stock Price Increases Over 20% Pre-Market: Why It Happened

HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Salarius CEO David Arthur will present during the virtual Diamond Equity Research Emerging Growth Invitational Conference taking place Wednesday, February 24, 2021. All registered conference attendees will be able to view the live virtual presentation.

News for Salarius Pharmaceuticals Inc Stock (SLRX)